(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Viking Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VKTX's revenue for 2025 to be $2,806,195,225, with the lowest VKTX revenue forecast at $2,806,195,225, and the highest VKTX revenue forecast at $2,806,195,225. On average, 1 Wall Street analysts forecast VKTX's revenue for 2026 to be $1,122,478,090, with the lowest VKTX revenue forecast at $1,122,478,090, and the highest VKTX revenue forecast at $1,122,478,090.
In 2027, VKTX is forecast to generate $12,108,732,396 in revenue, with the lowest revenue forecast at $8,249,091,483 and the highest revenue forecast at $15,968,373,308.